Please Wait.....
Report
Biosimulation Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035)
Market Report I 2026-05-20 I 350 Pages I EMR Inc.
The global biosimulation market attained a value of USD 4.09 Billion in 2025. The market is further expected to grow in the forecast period of 2026-2035 at a CAGR of 16.90%, to reach USD 19.49 Billion by 2035.
Q1 2026 Market Updates
Geopolitical Impact of Iran, US, and Israel War on the Biosimulation Market
United States: The Biosimulation Market, a key segment of the global economy, is experiencing a complex operating environment in Q1 2026 as a direct consequence of the US-Israel-Iran war. Petrochemical-derived pharmaceutical packaging materials including blister packs, polymer bottles, and specialty film coatings are facing 15-20% cost inflation from the Gulf supply disruption. API production costs are rising as petrochemical reagent prices increase 15-20%. Air freight costs have spiked dramatically, with temperature-sensitive pharmaceutical distribution facing elevated costs and extended lead times as Gulf carrier networks remain suspended. Consumer spending caution is growing as gasoline above USD 4 per gallon and 4.2% projected inflation compress household discretionary budgets. Clinical trial operations in Middle Eastern investigator sites have been disrupted, and medical supply chains face elevated logistics costs.
Iran: Iran's healthcare system has been severely damaged by the conflict, with the WHO identifying at least 13 health facilities as conflict-damaged. The domestic pharmaceutical and medical device sector, already severely constrained by sanctions limiting access to Western medical technology and APIs, has been further disrupted by power outages, workforce displacement, and the collapse of medical supply chain logistics. Iranian patients requiring treatment for biosimulation conditions face an acute access crisis, as hospital operations are redirected toward treating conflict casualties and basic medical supplies are running low.
Israel: Israel's pharmaceutical and medical device sector is operating under emergency conditions. Israeli hospitals have moved some operations underground, medical resources are being prioritised for conflict casualties, and elective and non-emergency healthcare consumption has declined. However, Israel's biopharmaceutical research base continues to operate, with several Israeli companies involved in novel treatment development for biosimulation indications. Post-conflict, Israel's healthcare system is expected to invest significantly in medical technology and pharmaceutical infrastructure restoration and capacity expansion.
Key Takeaways
Government
- Relevant health authorities should activate emergency pharmaceutical supply chain resilience protocols, ensuring that API and packaging material sourcing for essential biosimulation treatments is not concentrated in Gulf-adjacent supply chains exposed to maritime disruption.
- Regulatory agencies should fast-track review of treatment availability and consider emergency compassionate use extensions for patients in conflict-affected regions who face interruption to their standard of care.
- Governments should monitor petrochemical-derived pharmaceutical packaging cost inflation, ensuring that price increases remain within access thresholds for patients requiring ongoing biosimulation treatment.
Market
- Petrochemical-derived pharmaceutical packaging and API precursor costs are rising 15-20%, creating margin compression for biosimulation manufacturers in the near term, with limited ability to pass costs through in price-regulated markets.
- The conflict's disruption to clinical trial infrastructure in Middle Eastern sites may modestly delay regulatory submissions and new treatment launches that had enrolled patients from the region, though the structural market growth trajectory remains intact.
- Healthcare system demand for biosimulation treatment is fundamentally driven by disease burden and demographics rather than geopolitical events, providing strong structural insulation for the market's long-term growth trajectory.
Procurement
- Pharmaceutical procurement teams should build 90-day safety stock for essential biosimulation treatment drugs and biological agents, hedging against further pharmaceutical logistics cost increases and potential supply disruptions.
- API and excipient buyers should review single-source supplier risks for Gulf-adjacent petrochemical-derived pharmaceutical inputs, establishing secondary supply arrangements with non-Gulf origin manufacturers in India, China, and Europe.
- Hospital pharmacy procurement managers should review cold-chain logistics contracts for temperature-sensitive biosimulation therapeutics, ensuring that alternative air routing through non-conflict-zone hubs is available if Gulf carrier services remain suspended.
Biosimulation, a relatively new tool in healthcare and pharmaceutical drug development, allows researchers to simulate complex biological systems. It helps to predict drug behavior, reduces costs and time as compared to conventional experiments, and optimizes treatment strategies. These factors are likely to augment biosimulation market growth in coming years.
The rising adoption of biosimulation software by key market players can be attributed to its ability to predict clinical outcomes before the occurrence of human clinical trials. This approach not only expedites drug development timelines but also minimizes risks associated with failed trials. Such factors fuel the rising market demand. Moreover, the rise in healthcare expenditure and technological advancements in the field are also expected to fuel the market share.
Global Biosimulation Market Trends and Developments
Advancements in computational power, growing focus on chronic diseases, increasing demand for personalized medicine, and expansion in biosimulation applications comprise some of the key trends and developments in the market.
Advancements in Computational Power
Increased computational power and advancements in software capabilities are enabling more accurate biosimulation. This allows for biological simulation processes at a higher scale and speed, resulting in accelerated drug development timelines.
Growing Focus on Chronic Diseases
With the rising prevalence of chronic diseases, biosimulation is being leveraged to develop treatments for these conditions. Simulations help in predicting the long-term outcomes of therapies for chronic diseases. The predictive models also help in improving the design of clinical trials, leading to better patient care. Consequently, elevating the biosimulation market share positively.
Increasing Demand for Personalized Medicine
Biosimulation supports the development of personalized medicine by facilitating the simulation of drug responses based on individual genetic makeup. This market trend is expected to result in effective tailored treatment options, reducing the risk of adverse drug reactions.
Expansion in Biosimulation Applications
Beyond drug development, biosimulation is finding application in domains such as disease modelling, toxicology, and risk assessment of pharmaceuticals, demonstrating its expanded market reach.
December 2023
Certara acquired Applied Biomath, an innovative biotechnology company to industrialize quantitative systems pharmacology (QSP) biosimulation methods. Utilizing the expertise of Applied Biomath, the company intends to expand biosimulation capabilities including predicting the optimal dosing regimen for novel therapies.
June 2023
Simulations Plus Inc. acquired Immunetrics Inc. (a odelling and simulation company specializing in oncology, immunology, and autoimmune diseases) at a deal worth USD 15.5 million in cash along with USD 1.8 million hold-back, and USD 8 million depending on revenue performance. The acquisition will reinforce the existing quantitative systems pharmacology (QSP) software and service capabilities at Simulations Plus, increasing the therapeutic areas covered via QSP models by 50%.
March 2023
Certara, Inc.The leading biosimulation company launched Simcyp Simulator Version 22, a physiologically based pharmacokinetics (PBPK) platform with updated features and novel capabilities for drug development processes. The company Simcyp Simulator has proven its utilization across 300 label claims for 90+ novel drugs, replacing the need for human clinical trials.
January 2023
Cellworks announced the launch of two new business units, leveraging biosimulation for novel precision oncology drug testing to accelerate drug development timelines and reduce costs. Utilizing its biosimulation and computational model (CBM), the personalized therapy biosimulation company aims to predict patient response, streamline clinical trials, and aid in biomarker development, among others, potentially transforming the drug development process.
Factors Affecting Global Biosimulation Market Demand
As more and more pharmaceutical companies are recognising the significance of biosimulation software in expediting drug development processes, the market is witnessing major investments to integrate and improve simulation systems. The simulation models are increasingly employed to test drugs in a virtual environment before conducting expensive and time-consuming clinical trials, which is bolstering the biosimulation market value.
The market is also driven by the rising strategic partnerships between the leading market players, novel product launches, and the growing complexity of drug development fuelling the demand for biosimulation tools and services.
Global Biosimulation Market Segmentation
"Global Biosimulation Market Report and Forecast 2026-2035" offers a detailed analysis of the market based on the following segments:
Breakup by Product and Services
- Software
- Services
Breakup by Delivery Model
- Subscription Model
- Ownership Model
Breakup by Application
- Drug Discovery
- Drug Development
- Others
Breakup by End User
- Pharmaceutical and Biotechnology Companies
- Contract Research Organization
- Academic Research Institutes
- Others
Global Biosimulation Market: Competitive Landscape
The key market players are contributing to the biosimulation market growth through strategic mergers and acquisitions initiatives, novel product launches, and continuous R&D efforts aimed at technological advancement.
Other key players in the market include Advanced Chemistry Development Inc., Physiomics PLC, Genedata AG, Thermo Fisher Scientific, Immunetrics, BioSimulation Consulting Inc., Yokogawa Insillico Biotechnology GmbH, and Chemical Computing Group ULC, among others.
Global Biosimulation Market Analysis by Region
North America is the leading regional market, owing to the presence of key players and advanced healthcare system which is witnessing rapid digitization. The higher adoption rates of in-silico models in drug development and discovery processes is also driving market growth. Moreover, the rising prevalence of chronic diseases in the region is expected to fuel the biosimulation market size in the forecast period.
Asia Pacific is projected to experience exponential growth which can be attributed to the rising research and development activities in the region. Further, the increased impetus of the government to improve healthcare infrastructure and patient outcomes is likely to boost the market size.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Biosimulation Market Overview
3.1 Global Biosimulation Market Historical Value (2019-2025)
3.2 Global Biosimulation Market Forecast Value (2026-2035)
4 Global Biosimulation Market Landscape*
4.1 Global Biosimulation: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Biosimulation: Product Landscape
4.2.1 Analysis by Product and Services
4.2.2 Analysis by Delivery Model
4.2.3 Analysis by Applications
5 Global Biosimulation Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter's Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Biosimulation Market Segmentation (219-2035)
6.1 Global Biosimulation Market (2019-2035) by Product and Services
6.1.1 Market Overview
6.1.2 Software
6.1.2.1 Molecular Modeling and Simulation Software
6.1.2.2 PBPK Modeling and Simulation Software
6.1.2.3 Trial Design Software
6.1.2.4 Toxicity Prediction Software
6.1.2.5 Other Biosimulation Software
6.1.3 Services
6.1.3.1 In-House Services
6.1.3.2 Contract Services
6.2 Global Biosimulation Market (2019-2035) by Delivery Model
6.2.1 Market Overview
6.2.2 Subscription Model
6.2.3 Ownership Model
6.3 Global Biosimulation Market (2019-2035) by Application
6.3.1 Market Overview
6.3.2 Drug Discovery
6.3.2.1 Pre-Clinical Testing
6.3.2.2 Clinical Trials
6.3.3 Drug Development
6.3.3.1 Target Identification and Validation
6.3.3.2 Lead Identification and Optimization
6.3.4 Others
6.4 Global Biosimulation Market (2019-2035) by End User
6.4.1 Market Overview
6.4.2 Pharmaceutical and Biotechnology Companies
6.4.3 Contract Research Organization
6.4.4 Academic Research Institutes
6.4.5 Others
6.5 Global Biosimulation Market (2019-2035) by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Biosimulation Market (219-2035)
7.1 North America Biosimulation Market (2019-2035) by Product and Services
7.1.1 Market Overview
7.1.2 Software
7.1.2.1 Molecular Modeling and Simulation Software
7.1.2.2 PBPK Modeling and Simulation Software
7.1.2.3 Trial Design Software
7.1.2.4 Toxicity Prediction Software
7.1.2.5 Other Biosimulation Software
7.1.3 Services
7.1.3.1 In-House Services
7.1.3.2 Contract Services
7.2 North America Biosimulation Market (2019-2035) by Application
7.2.1 Market Overview
7.2.2 Drug Discovery
7.2.2.1 Pre-Clinical Testing
7.2.2.2 Clinical Trials
7.2.3 Drug Development
7.2.3.1 Target Identification and Validation
7.2.3.2 Lead Identification and Optimization
7.2.4 Others
7.3 North America Biosimulation Market (2019-2035) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Biosimulation Market (219-2035)
8.1 Europe Biosimulation Market (2019-2035) by Product and Services
8.1.1 Market Overview
8.1.2 Software
8.1.2.1 Molecular Modeling and Simulation Software
8.1.2.2 PBPK Modeling and Simulation Software
8.1.2.3 Trial Design Software
8.1.2.4 Toxicity Prediction Software
8.1.2.5 Other Biosimulation Software
8.1.3 Services
8.1.3.1 In-House Services
8.1.3.2 Contract Services
8.2 Europe Biosimulation Market (2019-2035) by Application
8.2.1 Market Overview
8.2.2 Drug Discovery
8.2.2.1 Pre-Clinical Testing
8.2.2.2 Clinical Trials
8.2.3 Drug Development
8.2.3.1 Target Identification and Validation
8.2.3.2 Lead Identification and Optimization
8.2.4 Others
8.3 Europe Biosimulation Market (2019-2035) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Biosimulation Market (219-2035)
9.1 Asia Pacific Biosimulation Market (2019-2035) by Product and Services
9.1.1 Market Overview
9.1.2 Software
9.1.2.1 Molecular Modeling and Simulation Software
9.1.2.2 PBPK Modeling and Simulation Software
9.1.2.3 Trial Design Software
9.1.2.4 Toxicity Prediction Software
9.1.2.5 Other Biosimulation Software
9.1.3 Services
9.1.3.1 In-House Services
9.1.3.2 Contract Services
9.2 Asia Pacific Biosimulation Market (2019-2035) by Application
9.2.1 Market Overview
9.2.2 Drug Discovery
9.2.2.1 Pre-Clinical Testing
9.2.2.2 Clinical Trials
9.2.3 Drug Development
9.2.3.1 Target Identification and Validation
9.2.3.2 Lead Identification and Optimization
9.2.4 Others
9.3 Asia Pacific Biosimulation Market (2019-2035) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Biosimulation Market (219-2035)
10.1 Latin America Biosimulation Market (2019-2035) by Product and Services
10.1.1 Market Overview
10.1.2 Software
10.1.2.1 Molecular Modeling and Simulation Software
10.1.2.2 PBPK Modeling and Simulation Software
10.1.2.3 Trial Design Software
10.1.2.4 Toxicity Prediction Software
10.1.2.5 Other Biosimulation Software
10.1.3 Services
10.1.3.1 In-House Services
10.1.3.2 Contract Services
10.2 Latin America Biosimulation Market (2019-2035) by Application
10.2.1 Market Overview
10.2.2 Drug Discovery
10.2.2.1 Pre-Clinical Testing
10.2.2.2 Clinical Trials
10.2.3 Drug Development
10.2.3.1 Target Identification and Validation
10.2.3.2 Lead Identification and Optimization
10.2.4 Others
10.3 Latin America Biosimulation Market (2019-2035) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Biosimulation Market (219-2035)
11.1 Middle East and Africa Biosimulation Market (2019-2035) by Product and Services
11.1.1 Market Overview
11.1.2 Software
11.1.2.1 Molecular Modeling and Simulation Software
11.1.2.2 PBPK Modeling and Simulation Software
11.1.2.3 Trial Design Software
11.1.2.4 Toxicity Prediction Software
11.1.2.5 Other Biosimulation Software
11.1.3 Services
11.1.3.1 In-House Services
11.1.3.2 Contract Services
11.2 Middle East and Africa Biosimulation Market (2019-2035) by Application
11.2.1 Market Overview
11.2.2 Drug Discovery
11.2.2.1 Pre-Clinical Testing
11.2.2.2 Clinical Trials
11.2.3 Drug Development
11.2.3.1 Target Identification and Validation
11.2.3.2 Lead Identification and Optimization
11.2.4 Others
11.3 Middle East and Africa Biosimulation Market (2019-2035) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Certara Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Dassault Systemes
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Simulation Plus
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Schrodinger Inc.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Advanced Chemistry Development Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Physiomics PLC
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Genedata AG
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Thermo Fisher Scientific
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Immunetrics
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 BioSimulation Consulting Inc.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Yokogawa Insillico Biotechnology GmbH
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Chemical Computing Group ULC
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
18 Global Biosimulation Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security